Post-Marketing Surveillance: Adverse Events during Long-Term Use of Atovaquone/Proguanil for Travelers to Malaria-Endemic Countries
Open Access
- 8 March 2006
- journal article
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 10 (suppl_1) , S16-S20
- https://doi.org/10.2310/7060.2003.35079
Abstract
Background. Atovaquone/proguanil in Europe is only licensed for 4 weeks of travel. Data on its long-term tolerability in nonimmune travelers are scarceKeywords
This publication has 2 references indexed in Scilit:
- Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind StudyClinical Infectious Diseases, 2001
- Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind studyThe Lancet, 2000